Spruce Street Capital LP bought a new position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,452,576 shares of the company's stock, valued at approximately $21,267,868,000. Savara makes up 4.2% of Spruce Street Capital LP's investment portfolio, making the stock its 8th biggest holding. Spruce Street Capital LP owned approximately 1.68% of Savara at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of SVRA. Algert Global LLC boosted its position in shares of Savara by 53.7% in the 2nd quarter. Algert Global LLC now owns 1,329,259 shares of the company's stock worth $8,188,000 after buying an additional 464,645 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Savara during the 2nd quarter valued at about $87,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Savara during the 2nd quarter valued at about $461,000. E Fund Management Co. Ltd. purchased a new position in Savara during the 2nd quarter valued at about $77,000. Finally, DCF Advisers LLC acquired a new position in Savara during the second quarter worth about $616,000. Institutional investors and hedge funds own 87.93% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on SVRA shares. Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.14.
Check Out Our Latest Stock Report on Savara
Savara Stock Performance
Savara stock opened at $5.56 on Tuesday. The stock has a fifty day moving average price of $5.70 and a 200 day moving average price of $5.47. Savara Inc. has a 52 week low of $3.08 and a 52 week high of $7.01. The firm has a market capitalization of $1.14 billion, a P/E ratio of -9.59 and a beta of 0.29. The company has a current ratio of 10.13, a quick ratio of 10.13 and a debt-to-equity ratio of 0.21.
Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities research analysts anticipate that Savara Inc. will post -0.62 earnings per share for the current year.
Savara Company Profile
(
Free Report)
Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Featured Stories
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
